INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), an organization accelerating the invention, growth and world entry to life-changing radiopharmaceuticals, at this time introduced the pricing of its public providing of 13,900,000 shares of Common Stock at a public providing value of $9.00 per share. The gross proceeds to the Company from the providing, earlier than deducting underwriting reductions and commissions and different estimated providing bills, are anticipated to be roughly $125 million. In addition, the Company has granted the underwriters a 30-day choice to buy as much as an extra 2,085,000 shares of its Common Stock. All of the shares to be offered within the providing are to be offered by POINT. The providing is predicted to shut on or about September 16, 2022, topic to customary closing circumstances.
Piper Sandler and Guggenheim Securities, LLC are appearing as joint book-running managers for the providing. Oppenheimer & Co. is appearing as lead supervisor for the providing.
POINT intends to make use of the web proceeds from the proposed providing, along with its current money, money equivalents and investments, to fund medical and preclinical analysis and growth applications, pre-commercialization actions, and for working capital and different basic company functions.
The securities are being provided by POINT pursuant to a registration assertion on Form S-3 beforehand filed and declared efficient by the Securities and Exchange Commission (“SEC”). A preliminary prospectus complement and accompanying prospectus referring to the proposed providing has been filed with the SEC and is offered totally free on the SEC’s web site at http://www.sec.gov. Copies of the preliminary prospectus complement and the accompanying prospectus relating to those securities may be obtained totally free from:
Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by phone at (800) 747-3924 or by e-mail at [email protected].
Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by phone at (212) 518-9544 or by e-mail at [email protected].
Oppenheimer & Co., Attention: Syndicate Prospectus Department, 85 Broad Street, twenty sixth Floor, New York, NY 10004, or by phone at (212) 667-8055, or by e-mail at [email protected].
This press launch doesn’t represent a proposal to promote or a solicitation of a proposal to purchase any securities of POINT, nor shall there be any sale of these securities in any state or jurisdiction through which such a proposal, solicitation or sale can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.
About POINT Biopharma Global Inc.
POINT Biopharma Global Inc. is a globally centered radiopharmaceutical firm constructing a platform for the medical growth and commercialization of radioligands that struggle most cancers. POINT goals to remodel precision medication by combining a portfolio of radiopharmaceutical property, a seasoned administration crew, an industry-leading pipeline, in-house manufacturing capabilities, and secured provide for uncommon medical isotopes like actinium-225 (225Ac) and lutetium-177 (177Lu). POINT’s energetic medical trials embrace FRONTIER, the part 1 trial for PNT2004, a pan-cancer program focusing on fibroblast activation protein-α (FAP-α), and SPLASH, the part 3 trial for PNT2002 for individuals with metastatic castrate resistant prostate most cancers (mCRPC) after second-line hormonal remedy.
Forward Looking Statements
This press launch accommodates forward-looking statements throughout the that means of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. In some instances, you may establish forward-looking statements by the next phrases: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the destructive of these phrases or different comparable terminology, though not all forward-looking statements comprise these phrases. These statements contain dangers, uncertainties and different components which will trigger precise outcomes, ranges of exercise, efficiency or achievements to be materially completely different from the data expressed or implied by these forward-looking statements. Although we consider that we’ve got an inexpensive foundation for every forward-looking assertion contained on this press launch, we warning you that these statements are based mostly on a mix of information and components at the moment identified by us and our projections of the longer term, about which we can’t be sure. We can’t guarantee you that the forward-looking statements on this press launch will show to be correct. These forward-looking statements are topic to a quantity of important dangers and uncertainties that would trigger precise outcomes to vary materially from anticipated outcomes, together with, amongst others, adjustments because of this of market circumstances or for different causes, the chance that the providing won’t be consummated, the dangers associated to COVID-19, the power to take care of the itemizing of POINT’s widespread inventory on the NASDAQ, adjustments in relevant legal guidelines or rules, the chance that POINT could also be adversely affected by different financial, business, and/or aggressive components, and different dangers and uncertainties, together with these described in POINT’s Annual Report on Form 10-Ok filed with the SEC on March 25, 2022 and subsequent filings with the SEC. Most of these components are exterior of POINT’s management and are troublesome to foretell. Furthermore, if the forward-looking statements show to be inaccurate, the inaccuracy could also be materials. In mild of the numerous uncertainties in these forward-looking statements, you shouldn’t regard these statements as a illustration or guarantee by us or some other particular person that we’ll obtain our aims and plans in any specified timeframe, or in any respect. The forward-looking statements on this press launch symbolize our views as of the date of this press launch. We anticipate that subsequent occasions and developments will trigger our views to vary. However, whereas we could elect to replace these forward-looking statements in some unspecified time in the future sooner or later, we’ve got no present intention of doing so besides to the extent required by relevant regulation. You ought to, subsequently, not depend on these forward-looking statements as representing our views as of any date subsequent to the date of this press launch.
Investor Relations Contact:
Daniel Pearlstein
Associate Director, Corporate Strategy
[email protected]
